HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: CDC recommends UV index use

This article was originally published in The Rose Sheet

Executive Summary

CDC recommends UV index use: In its May 5 Morbidity and Mortality Weekly Report, CDC recommends that individuals refer to the National Weather Services UV Index rating system to gauge UVA/UVB intensity when planning outdoor activity. The suggestion comes in response to recently released statistics on melanoma-associated deaths. Overall percentage increase in the rate of deaths associated with melanoma jumped 34.1% between 1973 and 1992, the report states. The increase is the third highest for all cancers during the same period. In 1992, the melanoma death rate for whites was 5.9 times higher than for all other races, and 2.1 times higher for men than women. In 1995, the American Cancer Society projects that 34,100 new cases will be diagnosed, and 7,200 deaths will be caused by melanoma...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel